Physician profile
Ryan T Deen
NPI 1164799037
$6,111.11
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $691 · 2021: $1,612 · 2022: $1,426 · 2023: $1,275 · 2024: $29.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,633.53 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $368.44 | 2019-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $337.62 | 2019-2022 | |
| Neuronetics, INC. | $312.06 | 2019-2021 | |
| Alkermes, INC. | $297.47 | 2019-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $288.79 | 2019-2023 | Nuedexta, Rexulti |
| Bausch Health US, LLC | $287.48 | 2019-2023 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $282.11 | 2019-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $274.44 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $200.19 | 2019-2023 | Fanapt, Hetlioz |
| Corium, LLC | $197.86 | 2022-2023 | Azstarys |
| Neos Therapeutics, LP | $177.60 | 2019-2023 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $136.45 | 2019-2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $130.29 | 2020-2022 | |
| Lundbeck LLC | $129.41 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $117.81 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.65 | 2020-2023 | |
| Validus Pharmaceuticals LLC | $115.99 | 2019-2023 | Equetro |
| Alfasigma USA, INC. | $102.37 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $69.87 | 2021-2023 | Jornay Pm |
| Eisai INC. | $67.88 | 2021 | |
| Merck Sharp & Dohme LLC | $67.69 | 2019-2022 | |
| Bioxcel Therapeutics, INC. | $63.11 | 2023 | Igalmi |
| Adlon Therapeutics L.P. | $62.53 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $56.27 | 2021-2023 | Austedo Xr |
| Shire North American Group INC | $53.67 | 2019 | |
| Tris Pharma INC | $27.52 | 2022-2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $22.81 | 2023 | Xelstrym |
| Harmony Biosciences LLC | $21.57 | 2021 | |
| Axsome Therapeutics, INC. | $21.33 | 2023 | Auvelity |
| Livanova USA, INC. | $21.14 | 2021 | |
| Owp Pharmaceuticals, INC. | $19.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.31 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $14.41 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Deen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.